公开(公告)号：WO2020159368A1

公开(公告)日：2020-08-06

申请号：PCT/NL2020/050051

申请日：2020-01-30

Applicant: LAVA THERAPEUTICS B.V. ,  STICHTING VUmc

Inventor： VAN DER VLIET, Johannes Jelle ,  DE WEERDT, Iris ,  DE GRUIJL, Tanja Denise ,  PARREN, Paul ,  KATER, Aron Philip ,  SCHEFFER, George Lodewijk

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

公开(公告)号：WO2020060405A1

公开(公告)日：2020-03-26

申请号：PCT/NL2019/050624

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B.V.

Inventor： VAN DER VLIET, Johannes Jelle ,  LAMERIS, Roeland ,  DE GRUIJL, Tanja Denise ,  PARREN, Paul Willem Henri Ida

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04

Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T- cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri-or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-,and tri-or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.

公开(公告)号：WO2020060406A1

公开(公告)日：2020-03-26

申请号：PCT/NL2019/050625

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B.V.

Inventor： DE WEERDT, Iris ,  KATER, Arnon Philip ,  PARREN, Paul Willem Henri Ida ,  DE GRUIJL, Tanja Denise ,  VAN DER VLIET, Johannes Jelle ,  LAMERIS, Roeland

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04

Abstract: The present invention relatestonovel methodsfor the treatment of hematological malignancies. In particular, the invention relatesto the treatment of hematological malignancies using antibodiescomprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human Vγ9Vδ2-TCR.

公开(公告)号：EP3853256A1

公开(公告)日：2021-07-28

申请号：EP19831921.2

申请日：2019-09-19

Applicant: Lava Therapeutics B.V.

Inventor： VAN DER VLIET, Johannes Jelle ,  LAMERIS, Roeland ,  DE GRUIJL, Tanja Denise ,  PARREN, Paul Willem Henri Ida

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04

公开(公告)号：EP3250608A1

公开(公告)日：2017-12-06

申请号：EP16715360.0

申请日：2016-01-27

Applicant: Lava Therapeutics B.V.

Inventor： VAN DER VLIET, Johannes Jelle ,  DE GRUIJL, Tanja Denise ,  VERHEUL, Hendrik Marinus Willem ,  DE BRUIN, Renée Cornelia Gerarda ,  LAMERIS, Roland

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/75

Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.

公开(公告)号：EP3853255A1

公开(公告)日：2021-07-28

申请号：EP19828845.8

申请日：2019-09-19

Applicant: Lava Therapeutics B.V.

Inventor： DE WEERDT, Iris ,  KATER, Arnon Philip ,  PARREN, Paul Willem Henri Ida ,  DE GRUIJL, Tanja Denise ,  VAN DER VLIET, Johannes Jelle ,  LAMERIS, Roeland

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04